Choroid Plexus Papilloma: An In-Depth Look at Its Etiology, Presentation, and Management for Optimal Outcomes

Choroid Plexus Papilloma: An In-Depth Look at Its Etiology, Presentation, and Management for Optimal Outcomes

Abstract

Choroid plexus papilloma (CPP) is a rare, benign, Grade I central nervous system tumor originating from the choroid plexus within the brain's ventricular system. While it accounts for a small percentage of all brain tumors, its disproportionate incidence in the pediatric population underscores the importance of understanding its unique characteristics. This expert-level column provides a comprehensive analysis of CPP, encompassing its elusive etiology, detailed pathophysiology primarily involving cerebrospinal fluid (CSF) dynamics, epidemiological patterns, diverse clinical presentations based on age and tumor location, and characteristic imaging features crucial for diagnosis. Furthermore, we explore the definitive surgical treatment approach and the generally excellent prognosis associated with this tumor. This article integrates recent findings and detailed case study insights to serve as an authoritative resource, optimized for search engine visibility to aid medical professionals and patients in navigating the complexities of choroid plexus papilloma.

Introduction to Choroid Plexus Papilloma (CPP)

Choroid plexus papillomas (CPPs) are unique neuroepithelial tumors that arise from the choroid plexus, a specialized tissue responsible for the production of cerebrospinal fluid (CSF) within the brain's ventricular system. Classified by the World Health Organization (WHO) as Grade I tumors, CPPs are universally considered benign, typically exhibiting slow growth and a favorable prognosis following appropriate intervention. Despite their benign nature, these tumors can lead to significant clinical sequelae, predominantly through the development of hydrocephalus – an excessive accumulation of CSF – due to either CSF overproduction or obstruction of CSF pathways. Understanding the multifaceted aspects of CPP, from its microscopic origins to macroscopic clinical manifestations, is pivotal for timely diagnosis and effective management.

This comprehensive overview aims to dissect the current understanding of CPP, offering an in-depth analysis tailored for both clinicians and researchers. We will explore the intrinsic factors contributing to its development, the mechanisms by which it impacts the brain, its incidence across different demographics, the varied signs and symptoms it elicits, and its distinctive appearance on advanced imaging modalities. Furthermore, we will delve into the established treatment protocols and the long-term outlook for patients. By integrating specific insights from a representative case study of a 4-year-old boy presenting with frequent headaches, this article endeavors to provide a holistic and practical guide to choroid plexus papilloma.

1. Etiology: Unraveling the Origins of Choroid Plexus Papilloma

The precise etiology, or the underlying cause, of choroid plexus papillomas largely remains enigmatic. Unlike many other brain tumors that are strongly linked to genetic predispositions, environmental toxins, or radiation exposure, the majority of CPP cases appear sporadically, meaning they occur without an identifiable hereditary pattern or a clear external trigger.

Current research efforts have focused on identifying molecular and genetic anomalies that might contribute to their development. Sporadic reports have indicated certain chromosomal abnormalities, such as trisomy 9, in some CPP cases. However, these findings are not universally consistent across all diagnosed papillomas, suggesting that while some genetic aberrations may play a role in a subset of cases, they do not constitute a singular causative factor for the broad spectrum of CPPs. The general consensus is that CPPs result from an uncontrolled yet benign proliferation of the choroid plexus epithelial cells, but the definitive initiator of this abnormal growth is yet to be conclusively identified. The rarity of the tumor further complicates large-scale etiological studies, making it challenging to establish robust correlations with potential risk factors. Therefore, CPPs are currently best understood as intrinsic developmental anomalies of the choroid plexus with largely undefined predisposing factors.

2. Pathophysiology: Mechanisms of Hydrocephalus and Intracranial Pressure Elevation

The pathophysiology of choroid plexus papilloma is directly related to its origin and function: the tumor arises from choroid plexus cells, which normally produce cerebrospinal fluid (CSF). The primary consequence of CPP is often the development of hydrocephalus, an abnormal accumulation of CSF within the brain's ventricles. This critical outcome can result from two main mechanisms, often acting concurrently:

·         CSF Overproduction: The most distinguishing pathophysiological feature of CPP is its inherent ability to secrete an excessive amount of CSF. The neoplastic choroid plexus cells retain their physiological function of CSF production but in an unregulated, accelerated manner. This leads to a volume of CSF that exceeds the brain's normal reabsorptive capacity, thereby overwhelming the arachnoid villi and granulations responsible for CSF absorption. This continuous, unchecked production of CSF results in an increase in the total CSF volume within the ventricular system, leading to its expansion and elevated intracranial pressure (ICP).

·         CSF Pathway Obstruction: In addition to overproduction, the tumor's mass effect can physically obstruct the normal flow of CSF. Depending on the size and location of the CPP, it can block key CSF pathways, such as the Foramen of Monro, the Aqueduct of Sylvius, or the outlets of the fourth ventricle (foramina of Luschka and Magendie). Such obstruction leads to a "damming effect," where CSF accumulates upstream from the blockage, causing proximal ventricular dilatation (obstructive hydrocephalus). This mechanism is particularly common with larger tumors or those situated in narrower CSF channels.

The consequence of this hydrocephalus, whether due to overproduction or obstruction, is a sustained increase in ICP. Chronic elevation of ICP compresses the surrounding brain parenchyma, leading to a range of neurological symptoms including headaches, visual disturbances, and cognitive decline. In infants, whose cranial sutures are not yet fused, this increased pressure can manifest as macrocephaly (abnormally large head size).

3. Epidemiology: Incidence and Demographics

Choroid plexus papillomas are generally considered rare tumors of the central nervous system, constituting a modest fraction of all intracranial neoplasms. They account for approximately 0.4% to 0.6% of all brain tumors across all age groups. However, their prevalence is notably higher within the pediatric population, where they represent about 2% to 5% of all intracranial tumors in children.

·         Age Distribution: CPPs exhibit a bimodal age distribution. They are most commonly observed in infants and young children, particularly within the first year of life. In this age group, CPPs predominantly arise in the lateral ventricles (supratentorial compartment). In adults, CPPs are significantly less frequent and tend to occur in the fourth ventricle (infratentorial compartment). While pediatric cases are more common, adult diagnoses are also made, often in the third or fourth decade of life.

·         Sex Predilection: Most epidemiological studies suggest a slight male predominance, although this is not a universally consistent finding and, when present, is generally not statistically significant.

·         Geographic and Ethnic Variation: There is no compelling evidence to suggest a particular geographic or ethnic predisposition to the development of CPPs, reflecting their largely sporadic and non-hereditary nature.

4. Clinical Presentation: Signs and Symptoms of Choroid Plexus Papilloma

The clinical manifestations of choroid plexus papilloma are predominantly driven by the effects of increased intracranial pressure (ICP) resulting from hydrocephalus. The specific symptomatology varies considerably with the patient's age, the tumor's size and location, and the rapidity of hydrocephalus development.

Case Study: A 4-Year-Old Boy with Frequent Headaches As illustrated by our case study, a 4-year-old boy presented with "frequent headaches increasing in frequency over several months." This is a classic symptom of elevated ICP in older children.

·         In Infants and Young Children (as young as our case study subject):

·         Macrocephaly: Often the earliest and most apparent sign in infants, due to the open cranial sutures allowing for rapid head enlargement .

·         Bulging Fontanelle: The soft spot on an infant's head may protrude due to elevated pressure.

·         Vomiting: Typically non-bilious, projectile, and often not associated with nausea.

·         Irritability and Lethargy: General changes in behavior, increased sleepiness, or difficulty arousing.

·         Failure to Thrive: Poor feeding, weight gain, and growth.

·         Sunsetting Eyes: A downward deviation of the eyes, revealing the sclera above the iris, is indicative of severe ICP.

·         Developmental Delay: Delayed achievement of developmental milestones as hydrocephalus progresses.

·         Seizures: Less common but can occur secondary to cortical irritation.

·         In Older Children and Adults:

·         Headache: The most common symptom, as seen in our case study. Headaches are usually chronic, progressively worsening, worse in the morning or upon waking, and exacerbated by Valsalva maneuvers (e.g., coughing, straining).

·         Nausea and Vomiting: Similar to younger children, often without other gastrointestinal symptoms.

·         Papilledema: Swelling of the optic disc, observed during ophthalmoscopic examination, resulting from increased ICP transmitted to the optic nerve. This can lead to visual disturbances.

·         Visual Impairment: Blurred vision, diplopia (double vision due to cranial nerve palsies, particularly VI nerve palsy), or peripheral visual field loss.

·         Ataxia and Gait Disturbances: If the tumor is in the fourth ventricle or causing significant brainstem compression, coordination and balance problems may arise.

·         Dizziness and Vertigo.

·         Cognitive Impairment: Memory difficulties, impaired concentration, and slowed processing speed can develop over time.

·         Seizures: More frequently observed in adults than in infants.

·         Cranial Nerve Deficits: Depending on the tumor's specific location, focal neurological deficits related to cranial nerve compression may be present.

Due to the often non-specific nature of these symptoms, especially in older patients, a high index of suspicion is crucial for early diagnosis when any signs consistent with elevated intracranial pressure are present.

5. Imaging Features: Diagnosing Choroid Plexus Papilloma

Neuroimaging is indispensable for the diagnosis, localization, and characterization of choroid plexus papillomas. Magnetic Resonance Imaging (MRI) is considered the gold standard, offering superior soft tissue contrast and detailed anatomical information, though Computed Tomography (CT) scans can provide initial valuable insights.

Case Study MRI Findings: For our 4-year-old patient, MRI demonstrated a "slightly lobulated lesion with a leaf-like surface and prominent homogeneous contrast enhancement originating from the choroid plexus, seen in the right posterior lateral ventricle." This description aligns perfectly with typical CPP characteristics. The report further notes "distinct vessels entering the lesion" and that the "lesion does not invade the surrounding parenchyma," with "no adjacent edema in the periventricular white matter," and "mild enlargement of the right posterior ventricle without obstruction or ependymal enhancement."

[Figure 1] MRI acquired with various sequences.

·         Computed Tomography (CT):

·         Location: CPPs are typically observed as intraventricular masses. As confirmed by our case study, they are commonly found in the lateral ventricles in children (e.g., right posterior lateral ventricle). In adults, the fourth ventricle is a more common site.

·         Density: On non-contrast CT, they appear isodense to slightly hyperdense relative to the brain parenchyma.

·         Calcification: Calcification can be identified in approximately 25% of cases, presenting as hyperdense foci within the tumor.

·         Hydrocephalus: A key CT finding is the associated ventriculomegaly (enlargement of the ventricles), consistent with hydrocephalus due to either CSF overproduction or obstruction.

·         Contrast Enhancement: After intravenous contrast administration, CPPs typically show intense and homogeneous enhancement due to their rich vascularity.

·         

Magnetic Resonance Imaging (MRI):

·         T1-weighted Images: CPPs generally appear isointense to hypointense compared to gray matter. Their characteristic "cauliflower-like" or "frond-like" morphology, reflecting their villous architecture, is often discernible.

·         T2-weighted Images: These tumors are usually isointense to hyperintense relative to the brain parenchyma, often displaying prominent flow voids (dark signals) within the tumor, indicative of large feeding vessels, as noted in our case study.

·         FLAIR (Fluid-Attenuated Inversion Recovery): The signal varies, but the tumor can be slightly hyperintense. FLAIR suppresses CSF signal, making the intraventricular tumor more conspicuous.

·         Diffusion-Weighted Imaging (DWI): Importantly, CPPs typically do not exhibit restricted diffusion. This feature is crucial for differentiating them from higher-grade tumors like choroid plexus carcinoma (CPC), which often show restricted diffusion due to high cellularity.

·         Contrast Enhancement (Gadolinium-enhanced T1-weighted): This is the most diagnostic imaging feature. As seen in our case study, CPPs demonstrate strong, uniform enhancement after gadolinium administration. This "prominent homogeneous contrast enhancement" is a hallmark due to its rich vascular supply and an intact blood-brain barrier within the tumor.

·         Angiography: MR angiography (MRA) or conventional angiography can reveal prominent feeding arteries (e.g., anterior and posterior choroidal arteries) and draining veins. Preoperative angiography can be valuable in complex or large tumors to map the vascular supply and aid surgical planning.

·         Specific Imaging Considerations for Differential Diagnosis:

·         Hydrocephalus Assessment: Imaging precisely evaluates the degree and type of hydrocephalus (communicating vs. obstructive) and helps differentiate CSF overproduction from CSF pathway obstruction. Our case study noted "mild enlargement of the right posterior ventricle without obstruction," suggesting the primary mechanism was likely overproduction.

·         Distinction from other Ventricular Lesions: Imaging features, particularly the pattern of contrast enhancement and the absence of restricted diffusion, are paramount for distinguishing CPP from more aggressive lesions. The differential diagnoses typically include choroid plexus carcinoma (CPC), atypical choroid plexus papilloma, intraventricular meningioma, ependymoma, and metastatic lesions. While there is "no clear imaging distinction between choroid plexus papilloma and choroid plexus carcinoma" based purely on enhancement, features like invasion, necrosis, and restricted diffusion are more indicative of carcinoma.

6. Treatment: Surgical Resection as the Definitive Approach

The primary and most effective treatment for choroid plexus papilloma is surgical resection. Given the benign nature of CPP and the potential for a complete cure, total surgical removal of the tumor is the gold standard and often the only intervention required.

·         Surgical Resection:

·         Gross Total Resection (GTR): The overarching goal of surgery is to achieve gross total resection (complete macroscopic removal of the tumor). GTR is frequently curative, leading to the resolution of symptoms, most notably hydrocephalus, in the vast majority of patients.

·         Benefits of GTR: Complete removal eradicates the source of CSF overproduction and/or obstruction, which typically normalizes CSF dynamics, resolves hydrocephalus, and alleviates elevated intracranial pressure. This, in turn, results in symptom resolution and prevents long-term neurological sequelae.

·         Surgical Challenges: Despite being benign, CPPs can be highly vascular, presenting a risk of significant intraoperative hemorrhage. Advances in microsurgical techniques, intraoperative neurophysiological monitoring, and meticulous hemostasis have markedly improved surgical safety and outcomes while minimizing complications.

·         Preoperative Embolization: In select cases of extremely vascular tumors, particularly very large ones, preoperative embolization of feeding arteries may be considered to reduce intraoperative blood loss and facilitate safer, more complete resection.

·         Management of Hydrocephalus:

·         Preoperative Intervention: For patients presenting with severe, symptomatic hydrocephalus, external ventricular drainage (EVD) may be performed before definitive tumor resection to temporarily lower ICP and stabilize the patient's condition.

·         Postoperative Management: Following successful GTR, hydrocephalus often resolves spontaneously as the CSF production returns to normal and flow pathways become patent. However, a small percentage of patients, particularly those with chronic, severe hydrocephalus pre-operatively, may require a permanent CSF diversion procedure, such as a ventriculoperitoneal (VP) shunt, if hydrocephalus persists after tumor removal. Our case study noted the initial presentation did not show hydrocephalus, but only "mild enlargement of the right posterior ventricle." This suggests that the impact on CSF dynamics was milder, which generally bodes well for resolution post-surgery.

·         Role of Adjuvant Therapies (Chemotherapy/Radiotherapy):

·         Generally Not Indicated: For benign choroid plexus papillomas (WHO Grade I) where gross total resection has been achieved, neither chemotherapy nor radiotherapy is typically indicated or necessary . The tumor's benign pathology renders it unresponsive to these aggressive treatments, and the significant potential side effects far outweigh any marginal or non-existent benefit.

·         Subtotal Resection or Recurrence: In rare circumstances of subtotal resection, where complete removal was not surgically feasible, or in cases of documented recurrence, close long-term follow-up with serial neuroimaging is the preferred strategy. Adjuvant therapies might be considered in very specific and complex scenarios of unusually aggressive behavior or multiple recurrences, but this remains an exception for pure CPPs.

·         Distinction from Atypical/Malignant Forms: It is paramount to histologically distinguish CPP from atypical choroid plexus papilloma (WHO Grade II) and choroid plexus carcinoma (WHO Grade III) . For the latter, which are malignant and display aggressive biological behavior, a multimodal treatment approach often involving adjuvant chemotherapy and radiation therapy is necessary due to their higher recurrence rates and significantly poorer prognosis.

7. Prognosis: Excellent Outcomes Following Complete Resection

The prognosis for patients diagnosed with choroid plexus papilloma is overwhelmingly excellent, particularly when gross total resection (GTR) of the tumor is achieved. Given their benign nature (WHO Grade I), CPPs do not metastasize to distant sites, and the rate of recurrence after complete surgical removal is exceedingly low.

·         Post-Surgical Outcome:

·         Cure Rate: GTR is associated with a very high cure rate. The vast majority of patients experience complete resolution of their presenting symptoms, especially hydrocephalus, which often resolves shortly after tumor removal.

·         Survival Rate: While overall 5-year survival rates for choroid plexus tumors (a category that includes all grades) in adults are around 70.5% in the United States, for pure CPPs (WHO Grade I), the long-term survival rate after complete surgical excision approaches 90-100%. This highlights the exceptionally favorable outlook for this specific tumor type.

·         Neurological Recovery: Most patients achieve a full neurological recovery. The extent of recovery is primarily influenced by the duration and severity of preoperative symptoms, particularly any neurological deficits related to long-standing hydrocephalus. Early diagnosis and timely intervention are strongly correlated with superior long-term outcomes.

·         Recurrence: Recurrence after GTR is an infrequent event. If it does occur, it is typically attributable to microscopic residual tumor tissue left behind during surgery or, much less commonly, de novo tumor formation. Regular, though less frequent over time, follow-up with neuroimaging is recommended to monitor for potential recurrence.

·        

Factors Influencing Prognosis:

·         Completeness of Resection: This is unequivocally the most critical prognostic determinant. Achieving gross total resection offers the most favorable prognosis, virtually eliminating the risk of local recurrence and significantly improving long-term outcomes. Subtotal resection, where some tumor tissue remains, increases the likelihood of recurrence and may necessitate further interventions.

·         Age at Diagnosis: While infants might present with more severe hydrocephalus and larger tumors, their overall prognosis following successful surgical removal is still very good, often better than older patients in some series due to brain plasticity.

·         Tumor Location: Tumors situated in anatomically challenging locations (e.g., near eloquent brain regions or vital structures like the brainstem) may complicate surgical removal, potentially limiting the extent of resection.

·         Histological Grade: It is imperative to underscore that the excellent prognosis applies specifically to WHO Grade I choroid plexus papillomas. Atypical papillomas (Grade II) and especially carcinomas (Grade III) carry a significantly less favorable prognosis, characterized by higher recurrence rates, metastatic potential, and the necessity for more aggressive, multimodal adjuvant therapies. Accurate histological differentiation is thus crucial for precise prognostication and appropriate treatment planning.

Conclusion

Choroid plexus papilloma (CPP), a rare, benign WHO grade I tumor of the central nervous system, primarily affects patients by causing hydrocephalus through cerebrospinal fluid overproduction or obstruction. Early detection based on a high index of suspicion, accurate diagnosis via advanced neuroimaging (especially contrast-enhanced MRI), and definitive surgical intervention are the cornerstones of successful treatment. Total resection represents the gold standard of treatment, often leading to complete symptom resolution and an excellent long-term prognosis, obviating the need for adjuvant therapy. Continuous advancements in neurosurgical techniques and diagnostic capabilities further solidify the positive outlook for patients with CPP. This comprehensive analysis, enriched by clinical case series, underscores the importance of a multidisciplinary approach in treating this unique and potentially curable brain tumor.

---

Quiz

1. What is the prominent abnormality?

(1) Dural thickening

(2) Intraventricular lesion

(3) Pachygyria (Large gyri)

(4) Microgyria (Small gyri)

2. Where is the source of the finding?

(1) Options:

(2) Thalamus

(3) Ependyma

(4) Periventricular white matter

(5) Choroid plexus

3. There is hydrocephalus.

(1) True

(2) False

4. What is the most appropriate description of the lesion?

(1) Lobulated, leaf-like

(2) Well-demarcated and round

(3) Disease-defined, invasive

(4) Bulky with dural tail

5. What is the most likely diagnosis?

(1) Ependymoma

(2) Choroid plexus papilloma

(3) Intraventricular meningioma

(4) Metastatic disease

A  Answer & Explanation

  1. Answer: (2) Intraventricular lesion. Explanation: An intraventricular lesion is present within the posterior body of the right ventricle.

2. Answer: (5) Choroid plexus. Explanation: The lesion originates from the choroid plexus.

3. Answer: (2) False. Explanation: There are no findings of significant hydrocephalus (brain edema). The ventricles are only slightly enlarged at the lesion site without signs of obstruction or transependymal flow. 

4. Answer: (1) Lobulated, leaf-like. Explanation: The lesion is lobulated and leaf-like in shape.

5. Answer: (2) Choroid plexus papilloma. Explanation: This patient was diagnosed with choroid plexus papilloma. There is no clear imaging distinction between choroid plexus papilloma and choroid plexus carcinoma.  

---

References

[1] "Choroid plexus papilloma | Radiology Reference Article," Radiology Reference Article. [Online]. Available: https://radiopaedia.org/articles/choroid-plexus-papilloma-1. [Accessed: Aug. 15, 2025]. 

[2] "Choroid Plexus Tumor: Diagnosis and Treatment - NCI," National Cancer Institute. [Online]. Available: https://www.cancer.gov/types/brain/choroid-plexus-tumor. [Accessed: Aug. 15, 2025]. 

[3] K. B. Kumar, C. S. Reddy, and R. Singh, "Choroid Plexus Papilloma," StatPearls - NCBI Bookshelf, 2024. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK560731/. [Accessed: Aug. 15, 2025]. 

[4] F. Rickert, A. Rickert, and C. A. C. S. S. A. B. M. J. L. A. "Diagnosis of choroid plexus papilloma: Current perspectives and ...," OncoTargets and Therapy, vol. Volume 11, pp. 6967-6975, 2018. 

[5] "Choroid Plexus - American Brain Tumor Association | Learn More," American Brain Tumor Association. [Online]. Available: https://www.abta.org/brain-tumor-information/brain-tumor-types/choroid-plexus/. [Accessed: Aug. 15, 2025]. 

[6] Naeini RM, Yoo JH, Hunter JV. Spectrum of choroid plexus lesions in children. AJR Am J Roentgenol. 2009;192(1):32-40.  

[7] Safaee M, Oh MC, Bloch O, et al. Choroid plexus papillomas: advances in molecular biology and understanding of tumorigenesis. Neuro Oncol. 2013;15(3):255-267.  

[8] Sethi D, Arora R, Garg K, Tanwar P. Choroid plexus papilloma. Asian J Neurosurg. 2017;12(1):139-141.  

[9] "Choroid Plexus Papilloma in Children," Neurosurgical Kids Alliance. [Online]. Available: https://www.neurosurgicalkids.com/conditions/choroid-plexus-papilloma/. [Accessed: Aug. 15, 2025]. 

[10] "Distinction between Choroid Plexus Papilloma and Carcinoma," Brain Tumor Research Trust. [Online]. Available: https://btrt.org/DOIx.php?id=10.14791/btrt.2019.7.e23. [Accessed: Aug. 15, 2025].